A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need for improved access to targeted therapies.
Kenneth Kehl, MD, MPH
Kenneth Kehl, MD, MPH, is a medical oncologist at Dana-Farber Cancer Institute.
Articles by Kenneth Kehl, MD, MPH